← Scroll for more →
Financial Statements — IMRN
Balance Sheet
(in millions AUD)| Metric | Q4 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q4 2022 | Q4 2021 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 2.83 | 11.66 | 15.21 | 17.16 | 22.11 | 25.05 |
| Inventory | 1.77 | 1.58 | 1.62 | 0.84 | 0.33 | 0.29 |
| Total Current Assets | 10.02 | 14.73 | 18.95 | 20.41 | 23.67 | 25.75 |
| Total Non-current Assets | 0.11 | 0.82 | 0.94 | 1.58 | 1.18 | 1.30 |
| Total Assets | 10.13 | 15.55 | 19.88 | 21.99 | 24.86 | 27.05 |
| Total Current Liabilities | 1.97 | 2.70 | 2.22 | 2.22 | 1.50 | 1.12 |
| Total Non-current Liabilities | 0.09 | 0.14 | 0.13 | 0.15 | 0.18 | 0.04 |
| Total Liabilities | 2.06 | 2.84 | 2.36 | 2.37 | 1.68 | 1.16 |
| Retained Earnings | (82.44) | (78.97) | (74.13) | (72.06) | (68.43) | (65.93) |
| Total Stockholder Equity | 8.07 | 12.71 | 17.53 | 19.62 | 23.18 | 25.90 |
← Scroll for more columns →
Income Statement
(in millions USD) (except per-share rows)| Metric | Q2 2024 |
|---|---|
| Total Revenue | 2.36 |
| Cost of Revenue* | 0.78 |
| Gross Profit | 1.58 |
| Research & Development | 2.65 |
| Total Operating Expenses* | 3.60 |
| Operating Income | (2.02) |
| Pretax Income | (2.07) |
| Net Income | (2.07) |
| Basic EPS | (0.91) |
| Diluted EPS | (0.91) |
← Scroll for more columns →
* Derived from reported values
Cash Flow Statement
(in millions USD)| Metric | Q2 2024 |
|---|---|
| Operating Cash Flow | (2.00) |
| Investing Cash Flow | 0.15 |
| Financing Cash Flow | (0.02) |
← Scroll for more columns →